News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioInvent Interim Report 1 January – 31 March 2012



5/2/2012 10:13:51 AM

LUND, Sweden--(BUSINESS WIRE)--Regulatory News:

BioInvent International AB (publ) (OMXS:BINV)

· Enrolment of patients in the phase II GLACIER study with BI-204 (acute coronary syndrome) was completed in March. The first results are expected to be published in the third quarter.

· Treatment of all patients in BioInvent’s phase II study with TB-402 (thrombosis) was completed in the quarter. First results are expected to be published later in Q2.


Read at BioSpace.com


comments powered by Disqus
BioInvent
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES